DEFA14A ·Filed Mar 11, 2026

PCRX

Pacira BioSciences, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001628280-26-016906
Proxy solicitation materials
Actionable Insight • Neutral

Traders should await the full filing disclosure to assess any potential impact on corporate governance, board composition, or shareholder initiatives. Monitor for subsequent filings or press releases from PCRX regarding the upcoming vote.

DirectionNeutral
Confidencelow
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
PCRX ▼ -3.31% at T+60d
NEUTRAL call ✗ call lost -3.31% · α vs SPY -14.01% · entry $23.53 → $22.75
Entry anchored
Mar 11, 03:59 PM ET
via exchange tick
T+1d
-1.15%
call -1.15% · α -0.55%
$23.26
settled 7mo ago
T+5d
-4.08%
call -4.08% · α -3.10%
$22.57
settled 7mo ago
T+20d
+1.10%
call +1.10% · α -0.87%
$23.79
settled 6mo ago
T+60d
-3.31%
call -3.31% · α -14.01%
$22.75
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Analysis based on filing metadata only — document content was unavailable. This DEFA14A filing for Pacira BioSciences, Inc. (PCRX) likely relates to proxy materials for an upcoming shareholder meeting, possibly involving director elections, executive compensation, or other corporate governance matters. Without access to the actual filing content, no specific developments or financial impacts can be assessed.

Key Facts

  • Filing type is DEFA14A, indicating supplemental proxy materials were submitted ahead of a shareholder meeting.
  • Such filings typically include updates or revisions to previously filed proxy statements, such as changes in board recommendations, additional proposals, or responses to shareholder inquiries.
  • No document content is available to determine specific agenda items, activist involvement, or management positions.

Financial Impact

Not specified

Risk Factors

  • Material developments, such as an activist campaign or contested board election, cannot be ruled out but are unconfirmed due to missing document content.
  • Delayed access to proxy details may limit ability to anticipate shareholder sentiment or voting outcomes.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

Report based on filing metadata.

16 reports for PCRX
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+60▲ +6.07%Apr 13, 2026
Filters
Rows
Reports for PCRX — sortable, filterable
TypeNow
Aug 6, 2026
8w ago
Press Release
BULLISH ★ 6/10
$25.58 $26.60▲ +3.99%▲ +3.39%$25.09 (−1.92%)
Jul 22, 2026
10w ago
Press Release
NEUTRAL ★ 1/10
$25.59 $24.36▼ −4.81%▼ −7.70%$25.09 (−1.95%)
Jun 30, 2026
13w ago
8-K
BULLISH ★ 7/10
$25.37 $26.47▲ +4.34%▲ +5.36%$25.09 (−1.10%)
Jun 13, 2026
15w ago
Insider Cluster
NEUTRAL ★ 3/10
$22.74 $25.54▲ +12.31%▲ +13.06%$25.09 (+10.33%)
Jun 4, 2026
17w ago
DEFA14A
MIXED ★ 6/10
$22.75 $25.59▲ +12.48%▲ +10.62%$25.09 (+10.29%)
Jun 4, 2026
17w ago
144
NEUTRAL ★ 2/10
$22.67 $25.39▲ +12.00%▲ +13.37%$25.09 (+10.67%)
Jun 1, 2026
17w ago
DEFA14A
NEUTRAL ★ 5/10
$22.25 $25.03▲ +12.49%▲ +14.06%$25.09 (+12.76%)
May 27, 2026
18w ago
DEFA14A
MIXED ★ 5/10
$23.68 $25.24▲ +6.59%▲ +9.73%$25.09 (+5.95%)
May 26, 2026
18w ago
DEFA14A
MIXED ★ 6/10
$24.04 $24.37▲ +1.37%▲ +3.27%$25.09 (+4.37%)
May 20, 2026
19w ago
DEFA14A
MIXED ★ 6/10
$23.48 $22.72▼ −3.24%▼ −3.57%$25.09 (+6.86%)
Showing 10 of 16

US Market Status

Market Open — Closes in 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access